• #835519
  • 14
  • Dr. Reddy's Laboratories #55111068507

Zoledronic Acid 4 mg / 5 mL Concentrate Intravenous Injection Single Use Vial 5 mL

ZOLEDRONIC ACID, SDV 0.8MG/ML 5ML

Features
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • More …
Container Type
Infusion Bottle Single Use Vial
Strength
4 mg / 5 mL Concentrate 5 mg / 100 mL Ready to Use
Volume
5 mL 100 mL
  Log In to Order
or

Professionals Also Viewed


Product Specifications


McKesson #835519
Manufacturer #55111068507
ManufacturerDr. Reddy's Laboratories
Country of OriginUnknown
Alternate Manufacturer Number2017234
ApplicationBone Resorption Inhibitor
Container TypeSingle Use Vial
Dosage FormInjection
Generic Drug Code19476
Generic Drug NameZoledronic Acid
NDC Number55111-0685-07
Product DatingMcKesson Acceptable Dating: we will ship >= 90 days
Strength4 mg / 5 mL Concentrate
TypeIntravenous
UNSPSC Code51182415
Volume5 mL
Features
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Vials of zoledronic acid injection concentrate for infusion contain overfill allowing for the withdrawal of 5 mL of concentrate (equivalent to 4 mg zoledronic acid)
  • This concentrate should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP following proper aseptic technique, and administered to the patient by infusion
  • Do not store undiluted concentrate in a syringe, to avoid inadvertent injection
  • If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C-8°C (36°F-46°F)
  • Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes